These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 11205463)
1. Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen. Hügli A; Sappino AP; Anchisi S; Mermillod B; Schafer P; Anguenot JL; Bonnefoi H Ann Oncol; 2000 Dec; 11(12):1557-61. PubMed ID: 11205463 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Bonnefoi H; Smith IE; O'Brien ME; Seymour MT; Powles TJ; Allum WH; Ebbs S; Baum M Br J Cancer; 1996 Feb; 73(3):391-6. PubMed ID: 8562348 [TBL] [Abstract][Full Text] [Related]
3. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer. Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362 [TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. Jones AL; Smith IE; O'Brien ME; Talbot D; Walsh G; Ramage F; Robertshaw H; Ashley S J Clin Oncol; 1994 Jun; 12(6):1259-65. PubMed ID: 8201387 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. Humphreys AC; Dent J; Rodwell S; Crawford SM; Joffe JK; Bradley C; Dodwell D; Perren TJ Br J Cancer; 2004 Jun; 90(11):2131-4. PubMed ID: 15150554 [TBL] [Abstract][Full Text] [Related]
7. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. Nolè F; Munzone E; Mandalà M; Catania C; Orlando L; Zampino MG; Minchella I; Colleoni M; Peruzzotti G; Marrocco E; Goldhirsch A Ann Oncol; 2001 Jan; 12(1):95-100. PubMed ID: 11249057 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307 [TBL] [Abstract][Full Text] [Related]
9. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J Eur J Cancer; 1992; 29A(1):37-43. PubMed ID: 1445744 [TBL] [Abstract][Full Text] [Related]
10. Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer. Klaassen U; Wilke H; Müller C; Borquez D; Korn M; Achterrath W; Harstrick A; Diergarten K; Seeber S Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):38-40. PubMed ID: 9144690 [TBL] [Abstract][Full Text] [Related]
11. Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Klaassen U; Wilke H; Weyhofen R; Harstrick A; Eberhardt W; Müller C; Korn M; Hanske M; Diergarten K; Seeber S Anticancer Drugs; 1998 Mar; 9(3):203-7. PubMed ID: 9625430 [TBL] [Abstract][Full Text] [Related]
12. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin. Klaassen U; Wilke H; Seeber S J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer. Zhang CX; Huang S; Xu N; Fang JW; Shen P; Bao YH; Mou BH; Shi MG; Zhong XL; Xiong PJ Anticancer Drugs; 2007 Jun; 18(5):581-6. PubMed ID: 17414627 [TBL] [Abstract][Full Text] [Related]
14. Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer. Stuart NS; McIllmurray MB; Bishop JL; Johnston SR; Price CG; O'Reilly SM; Joffe JK; Neave F; Whipp EC Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):152-6. PubMed ID: 18083354 [TBL] [Abstract][Full Text] [Related]
15. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Smith IE; A'Hern RP; Coombes GA; Howell A; Ebbs SR; Hickish TF; O'Brien ME; Mansi JL; Wilson CB; Robinson AC; Murray PA; Price CG; Perren TJ; Laing RW; Bliss JM; Ann Oncol; 2004 May; 15(5):751-8. PubMed ID: 15111342 [TBL] [Abstract][Full Text] [Related]
16. A pilot study of continuous infusional 5-fluorouracil, doxorubicin and cyclophosphamide in breast cancer. Mackay HJ; Bissett D; Twelves C; Vasey PA Clin Oncol (R Coll Radiol); 1999; 11(3):174-8. PubMed ID: 10465471 [TBL] [Abstract][Full Text] [Related]
17. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. De Boer RH; Eisen TG; Ellis PA; Johnston SR; Walsh G; Ashley S; Smith IE Ann Oncol; 2002 Jun; 13(6):889-94. PubMed ID: 12123334 [TBL] [Abstract][Full Text] [Related]
18. A pilot study of infusional CMF (CMF-inf): active and well tolerated in breast cancer. The Edinburgh Breast Group. Mackay J; Cameron DA; Gardiner J; Leonard T; Lee LE; Leonard RC Ann Oncol; 1996 Apr; 7(4):409-11. PubMed ID: 8805934 [TBL] [Abstract][Full Text] [Related]
19. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience. Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333 [TBL] [Abstract][Full Text] [Related]
20. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Venturini M; Del Mastro L; Garrone O; Angiolini C; Merlano M; Bergaglio M; Tolino G; Lambiase A; Baldini A; Canavese G; Rosso R Ann Oncol; 2002 Apr; 13(4):546-52. PubMed ID: 12056704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]